Factors associated with the level of prolactin in patients under remission from Alcohol Use Disorder: A gender perspective by Pandey, Susmita et al.
352  |    Neuropsychopharmacology Reports. 2021;41:352–361.wileyonlinelibrary.com/journal/nppr
1  | INTRODUC TION
Prolactin is a polypeptide hormone mainly secreted by the lactotro-
phs in the anterior pituitary and also by the extra pituitary sources like 
lymphocytes, the breast, the prostate, and the adipose tissue cells.1 
Although prolactin is well known for its role in lactation, mammary 
gland development, and reproduction, it also plays a vital role in the 
immune functions and behavioral functions of learning, memory, and 
adaptation.2 The release of prolactin, to a major extent, is inhibited by 
the neurotransmitter dopamine produced in the hypothalamus.3,4 To 
this end, the level of prolactin in the peripheral blood may be viewed as 
a reflection of the hypothalamic dopaminergic activity.
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Abstract
Background: Prolactin mirrors the dopaminergic activity in the brain which is key to 
understanding alcohol use disorders (AUD). Still, patients with AUD are a heterog-
enous group and there seem to be gender differences in the relationship between 
alcohol use and the level of prolactin. In this study, we examined gender- wise re-
lationship of alcohol use trait- and state- related factors with the level of prolactin 
among AUD inpatients in remission.
Methods: This cross- sectional study examined the level of prolactin along with gen-
eral patient characteristics and alcohol use trait- and state- related factors that could 
influence the level of prolactin in 112 AUD inpatients at three rehabilitation clinics in 
Norway. Logistic regression was performed to identify the gender- specific predictors 
of level of prolactin.
Results: Male and female AUD patients had similar level of prolactin. Among females, 
younger age, early alcohol debut, and absence of parental drinking problem pre-
dicted higher level of prolactin. In males, presence of other substance dependence 
predicted a lower level of prolactin.
Conclusions: There were gender differences in the factors associated with the level 
of prolactin among the AUD patients. Especially in the female AUD patients under 
remission, alcohol use trait- related factors were better predictors of the level of pro-
lactin than the alcohol use state- related factors, indicating that individuals might 
characteristically have varying degree of dopamine reactivity.
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The dopamine system is considered to have an important role 
in the development and maintenance of alcohol use disorder (AUD). 
Alcohol intake increases dopaminergic activity, which induces de-
pendence.5- 7 However, chronic heavy alcohol use downregulates the 
dopamine system, possibly through reduction in the availability and 
sensitivity of dopamine D2 receptors (D2R).2,8- 10 Different experi-
mental11- 13 and naturalistic studies14- 16 indicate that a down regula-
tion of the D2R increases the level of prolactin.
An animal study identified reduced hypothalamic dopamine as a 
possible cause of elevated serum prolactin after chronic alcohol ad-
ministration.11 However, studies also suggest that alcohol- induced 
proliferation of lactotrophs in the anterior pituitary gland may have 
fostered prolactin elevation.17 Nevertheless, a neuroendocrine chal-
lenge test performed by administering the D2R blocker haloperidol 
to AUD patients revealed significant increase in the level of prolac-
tin in patients when they underwent detoxification compared to the 
period of their usual alcohol consumption.12 Such an increase in pro-
lactin response to D2R blockage after undergoing detoxification sig-
nifies increased availability and responsivity of dopamine receptors 
indicating normalization from the previously downregulated dopa-
mine system in these patients. However, increased level of prolactin 
in the absence of a neuroendocrine challenge is a sign of downregu-
lated dopamine system.
Studies have shown that in addition to chronic heavy alcohol 
use, prolactin may also elevate in acute alcohol intoxication,18 al-
cohol withdrawal, and early abstinence.14 The elevation of pro-
lactin during alcohol withdrawal is associated with the severity 
of alcohol dependence and withdrawal symptoms.14 Also, it has 
been suggested that the elevated level of prolactin at the time of 
admission for treatment can serve as a biomarker that predicts in-
creased risk of withdrawal seizures.19 In addition, elevated level of 
prolactin is found to be associated with higher craving during early 
alcohol withdrawal in AUD patients with anxiety disorder who 
used alcohol for its anxiolytic effect.20 Likewise, increased level of 
prolactin during alcohol withdrawal is significantly correlated with 
depressed mood.21
Generally, the level of prolactin is also influenced by use of 
certain drugs1 and presence of diseases such as pituitary tumor, 
hypothyroidism, lung cancer, renal failure, and cirrhosis of liver. 
In addition, several physiological factors including body mass 
index (BMI),22 menstrual cycle,23 stress,24 and sleep25 influence 
the level of prolactin. One among such important factors that in-
fluences the level of prolactin is gender.26 A study reported that 
increased level of prolactin is associated with lower craving during 
alcohol withdrawal but only in female AUD patients.15 Another 
study which examined the alteration in the level of prolactin and 
its associated factors during alcohol withdrawal chose to include 
only male AUD patients so as to overcome the impact of gender 
difference.14 In general, it is found that females have enhanced 
dopamine activity27 and modulation of dopamine by sex hormones 
especially estrogen28 implicates that the influence of alcohol on 
dopamine and prolactin may be sexually dimorphic. A previous 
study in AUD patients by our group found that a high level of pro-
lactin was associated with relapse in a subgroup of patients with 
antisocial personality disorder, a disorder most often present in 
males (Pandey S. et al, 2020, unpublished data). Thus, there seem 
to be different predictors of level of prolactin in different sub-
groups of AUD patients.
Here, we aim to examine the gender- specific factors that influ-
ence the level of prolactin in AUD inpatients. Given the fact that 
the level of prolactin may be influenced by a plethora of factors, it 
is difficult to identify the role of alcohol on fluctuations of level of 
prolactin and also caution should be held while using prolactin as a 
surrogate marker to the dopaminergic activity. Furthermore, individ-
uals’ characteristics related to alcohol use determined by their genes, 
background, experiences, or the interactions among them (trait 
factors) may influence the level of prolactin, in addition to their cur-
rent alcohol consumption status (state factors). We have therefore 
categorized the prolactin influencing factors into (a) general patient 
characteristics, (b) alcohol use trait- related factors, (c) alcohol use 
state- related factors, and (d) presence of other substance depen-
dence in this study and have aimed to scrutinize whether the factors 
in these categories can predict the level of prolactin. We hypothesize 
that alcohol use trait- and state- related factors influence the level of 
prolactin in AUD patients but differently in males and females.
2  | MATERIAL S AND METHODS
2.1 | Study participants
AUD patients (n = 112; 31 females) in treatment at three differ-
ent rehabilitation clinics in Norway participated in the study. The 
median (25th, 75th percentiles) age of the participants was 53.3 
(44.5, 57.8) years. The participants had been receiving inpatient 
treatment since median (25th, 75th percentiles) days of 7 (5, 12) 
and reported being abstinent since 19 (13, 30) days before data 
collection. Ethical approval to conduct the study was obtained 
from Norwegian Regional Ethics Committee (Reference number 
2017/1314). The study abided by the Declaration of Helsinki. The 
participants provided written informed consent to participate in 
the study.
The inclusion criteria were adult above 18 years of age currently 
receiving inpatient treatment for AUD. The patients were also re-
quired to self- report abstinence for at least 5 days before data 
collection because the residential treatment in Norway does not 
necessarily confine the patients within the treatment center indicat-
ing that the patient may have a possibility to relapse even during the 
inpatient treatment. The exclusion criteria were unfamiliarity with a 
Scandinavian language, severe somatic illness, psychosis, and cog-
nitive impairment that could hinder the patient's ability to provide 
informed consent and safely participate in the study. Furthermore, 
we did not include those patients from whom blood sample could 
not be obtained via superficial veins of arm.
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2.2 | Measures
2.2.1 | General patient characteristics with possible 
influence on prolactin
Information on patient age, smoking status, height, and weight was 
obtained, and BMI (kg/m2) was calculated. In addition, information 
on current regular use of dopaminergic drugs including antipsychot-
ics, antihistamines, and stimulants was collected. The influence of 
all typical antipsychotics and mainly two atypical antipsychotics, 
risperidone and amisulpride, were our major focus because their ef-
fect on the dopamine receptors is well established and significant.29 
Furthermore, psychological distress and sleep condition of the pa-
tients were assessed. A Norwegian version of the 10- item Hopkins 
Symptom Checklist (HSCL), which has been previously used in AUD 
population,30 was used to identify general psychological distress. 
The checklist required the respondents to rate their experience of 
symptoms related to anxiety and depression over the past week on a 
scale of 1 (not at all) to 4 (extremely). The mean score was calculated 
if 8 out of 10 items were answered. Higher score corresponds to 
more psychological distress. Participants’ sleep condition over the 
last month was assessed using an 8- item Sleep Condition Indicator31 
which required the respondents to rate their sleep quality and its im-
pact on their life in a scale of 0 to 4. The total score was generated by 
summing up the individual scores if 6 out of 8 items were answered 
and higher score represented better sleep conditions.
2.2.2 | Alcohol use trait- related factors with possible 
influence on prolactin
Alcohol use trait- related factors refer to those patient character-
istics related to alcohol use which are determined by their genes, 
background, experiences, or the interactions among them. In this 
study, we collected information on participants’ age (years) at first 
alcohol use, presence of alcohol problems in parents, and level of 
response to early alcohol use as alcohol use trait- related factors. The 
level of response to early alcohol use was examined using a Self- 
Rating of the Effects (SRE) of alcohol form.32 This is a 12- item instru-
ment from which we chose a single item that measured the number 
of standard drinks required to develop dizziness during the first five 
times the alcohol was imbibed. Higher number of drinks required to 
feel dizzy is interpreted as lower level of response to alcohol.
2.2.3 | Alcohol use state- related factors with 
possible influence on prolactin
Alcohol use state- related factors refer to the current alcohol- related 
characteristics of the patients mainly attributable to the actual action 
of alcohol consumption either current or over time. In this study, we 
collected information on hazardous alcohol use, duration of drinking 
(years), time since last drink (days), and presence of current alcohol 
withdrawal symptoms as alcohol use state- related factors. Hazardous 
alcohol consumption was screened using the WHO- developed Alcohol 
Use Disorders Identification test (AUDIT) which measures the experi-
ence with alcohol within the last year using 10 questions.33 The first 
3 questions deal with the level of alcohol consumption (AUDIT- C) 
while the last 7 questions are related to alcohol dependence (AUDIT- 
dependence) and alcohol- related harms (AUDIT- harm) summed to-
gether and hereafter referred as AUDIT- problems.34 Each response 
has scores that range from 0 to 4. The total score was calculated as 
sum of individual items if all three items were answered for AUDIT- C 
and if six out of seven items were answered for AUDIT- problems. The 
total score ranged from 0 to 12 for AUDIT- C and 0 to 28 for AUDIT- 
problems. A higher score indicates more hazardous alcohol use.
The presence of other substance dependence was identified 
using the Mini International Neuropsychiatric Interview (MINI) 
Norwegian translation version 6.0. which is a short structured diag-
nostic interview for DSM- IV psychiatric disorders. The nonalcohol 
psychoactive substance use disorders module of the MINI gives the 
diagnosis of current substance dependence and current substance 
abuse by asking questions about use of psychoactive substances 
within the period of past 12 months. The diagnosis of either current 
substance dependence or substance abuse was considered as pres-
ence of other substance dependence in our study.
2.2.4 | Prolactin and other biological measures 
related to alcohol use
Along with prolactin, we measured gamma- glutamyltransferase (γ- 
GT) and phosphatidylethanol (PEth; 16:0/18:1) of the participants. 
Venous blood samples from the superficial veins in the arm were 
collected. Serum gel tubes were used to collect blood sample for 
prolactin and γ- GT, and ethylenediaminetetraacetic acid tubes were 
used for PEth. The tubes were turned upside- down 8 to 10 times 
immediately after the samples were drawn and then set to rest in a 
blood tube stand. The serum gel tubes were centrifuged to separate 
serum. The blood samples were then sent to a laboratory to perform 
necessary analysis.
Prolactin was measured by chemiluminescence immunoassay 
using the ADVIA Centaur XPT immunoassay analyzer (Siemens, 
Erlangen, Germany), and the analytical and biological coefficients of 
variation of the assay were 3.7% and 23%, respectively. The prolac-
tin secretion is greatest during the sleep,35 and it is recommended 
that the blood sample for prolactin estimation should be collected 
2- 3 hours after waking up.36 All our blood samples were drawn after 
8:45 in the morning. The median (25th, 75th percentiles) time for 
sample collection was 10:38 AM (10:10 AM, 12:30 PM).
2.3 | Statistical analyses
Statistical analyses were performed using SPSS version 23.0 
for Windows. Descriptive statistics were used to present the 
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TA B L E  1   Gender differences in selected variables among AUD inpatients under remission (n = 112)
Patient group
Female (n = 31) Male (n = 81)
P- valuesn n
General patient characteristics
Age (y) Median (25th, 75th 
percentile)
31 51.7 (43.6, 57.1) 81 53.4 (44.7, 59.2) 0.318a 
Body mass index (kg/m2) Median (25th, 75th 
percentile)
31 26.5 (23.1, 29.4) 81 26.5 (13.5, 28.9) 0.633a 
Smoking n (%) 31 21 (67.7) 81 68 (84.0) 0.057b 
HSCL mean score Median (25th, 75th 
percentile)
21 2.5 (1.9, 3.1) 64 1.9 (1.5, 2.4) 0.002a 
Sleep condition Median (25th, 75th 
percentile)
20 13.0 (7.8, 17.5) 62 18.0 (11.0, 25.0) 0.036a 




n (%) 31 0 (0) 83 1 (1.2) 1.000b 
Alcohol use trait- related factors
Age at first drink (y) Median (25th, 75th 
percentile)
31 15.0 (14.0, 17.0) 80 15.0 (13.0, 16.0) 0.214a 
Parents having drinking 
problem
n (%) 31 18 (58.1) 80 43 (53.8) 0.682b 
SRE (number of alcohol units 
to feel dizzy)
Median (25th, 75th 
percentile)
15 5.0 (2.0, 6.0) 46 4.3 (3.0, 7.0) 0.661a 
Alcohol use state- related factors
AUDIT- C Median (25th, 75th 
percentile)
21 11.0 (8.5, 12.0) 63 11.0 (9.0, 12.0) 0.531a 
AUDIT- problems Median (25th, 75th 
percentile)
21 19.0 (15.0, 23.0) 64 19.0 (14.0, 22.0) 0.624a 
Duration of drinking carrier 
(y)
Median (25th, 75th 
percentile)
31 9.0 (5.0, 15.0) 80 17.5 (10.0, 25.0) <0.001a 
Time since last drink (d) Median (25th, 75th 
percentile)
31 16.0 (12.0, 30.0) 80 19.5 (13.0, 36.5) 0.202a 
Current withdrawal 
symptoms present
n (%) 31 3 (9.7) 81 11 (13.6) 0.754c 
Presence of other substance dependence
Other substance dependence 
present
n (%) 31 3 (9.7) 80 21 (26.3) 0.057b 
Biological measures of alcohol use
γ- GT (U/L) Median (25th, 75th 
percentile)
30 31.5 (22.0, 57.5) 81 41.0 (25.5, 89.5) 0.133a 
PEth (μmol/L) Median (25th, 75th 
percentile)
28 0.2 (0.1, 0.6) 79 0.3 (0.1, 0.6) 0.952a 
Level of prolactin (mU/L) Median (25th, 75th 
percentile)
31 125.0 (103.0, 202.0) 81 134.0 (98.0, 177.0) 0.743a 
Note: Values in bold indicate statistically significant results.
Abbreviations: γ- GT, Gamma- glutamyltransferase; AUDIT, alcohol use disorders identification test; HSCL, Hopkins Symptom Checklist; PEth, 
Phosphatidylethanol; SRE, self- rating of the effects of alcohol.
aMann- Whitney U test.
bPearson chi- square.
cFisher's exact test.
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TA B L E  2   Gender differences in the association of selected variables with prolactin levels among AUD inpatients under remission 
(n = 112)
Factors with possible influence on Prolactin
Level of Prolactin
Female (n = 31) Male (n = 81)
n P- values n P- values
General patient characteristics
Age (y) rs 31 −0.533 0.002
b  81 −0.021 0.852b 
Body mass index (kg/m2) rs 31 0.324 0.075
b  81 0.023 0.839b 
Smoking
No Median (25th, 75th 
percentile)
10 125.0 (88.0, 195.0) 0.485a  13 158.0 (126.0, 191.0) 0.163a 
Yes Median (25th, 75th 
percentile)
21 125.0 (103.5, 
204.0)
68 132.0 (94.3, 168.8)
HSCL mean score rs 21 −0.007 0.978
b  64 −0.122 0.339b 
Sleep condition rs 19 0.037 0.743
b  62 0.047 0.719b 
Alcohol use trait- related factors
Age at first drink (y) rs 31 −0.423 0.018
b  80 0.104 0.357b 
SRE (number of alcohol 
units to feel dizzy)
rs 15 0.402 0.138
b  46 0.302 0.041b 
Parents having drinking problem
No Median (25th, 75th 
percentile)
13 175.0 (115.5, 
223.0)
0.075a  37 134.0 (99.5, 172.5) 0.772a 
Yes Median (25th, 75th 
percentile)
18 111.0 (99.3, 195.0) 43 139.0 (99.0, 188.0)
Alcohol use state- related factors
AUDIT- C rs 21 0.366 0.103
b  63 −0.084 0.511b 
AUDIT- problems rs 21 −0.184 0.424
b  64 −0.119 0.351b 
Duration of drinking 
carrier (y)
rs 31 −0.134 0.471
b  80 −0.127 0.261
Time since last drink (d) rs 31 −0.018 0.925
b  80 0.091 0.422b 
Current withdrawal symptoms
Absent Median (25th, 75th 
percentile)
28 124.5 (103.3, 
197.0)
0.316a  70 133.5 (98.5, 175.5) 0.994a 
Present Median (25th, 75th 
percentile)
3 204.0 (103.0) 11 140.0 (91.0, 196.0)
Other substance dependence
Absent Median (25th, 75th 
percentile)
28 122.5 (103.0, 
190.0)
0.018a  59 140.0 (112.0, 180.0) 0.052a 
Present Median (25th, 75th 
percentile)
3 242.0 (204.0) 21 115.0 (70.0, 164.0)
Biological measures of alcohol use
γ- GT (U/L) rs 30 0.074 0.699
b  81 0.048 0.669b 
PEth (μmol/L) rs 28 −0.056 0.776
b  79 −0.038 0.741b 
Note: Values in bold indicate statistically significant results.
Abbreviations: γ- GT, Gamma- glutamyltransferase; AUDIT, alcohol use disorders identification test; HSCL, Hopkins Symptom Checklist; PEth, 
Phosphatidylethanol; SRE, self- rating of the effects of alcohol.
rs, Spearman's rank order correlation coefficient.
aMann- Whitney U test.
bSpearman's rank order correlation.
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characteristics of the AUD patients stratified on gender. Our 
data were skewed and thus reported as medians and 25th, 75th 
percentiles in the tables. Groups were compared using Pearson's 
χ2 test or Fisher's exact test for categorical variables and Mann- 
Whitney's U test for continuous variables. In addition, Spearman's 
Rho (rs) was used to identify the gender- wise correlates of level of 
prolactin. Furthermore, a gender- wise logistic regression analysis 
of level of prolactin was performed, and odds ratios (OR) along 
with 95% confidence intervals (CI) were reported. Linear regres-
sion analysis was not performed because the assumptions of the 
test were not met. To obtain a dichotomous outcome variable for 
logistic regression, the prolactin values for each gender were split 
on median. Along with unadjusted logistic regression analysis, 
an age- adjusted logistic regression model was also constructed. 
All statistical tests were two- tailed with a significance level of 
α = 0.05.
3  | RESULTS
Table 1 presents the gender differences of selected variables in the 
AUD patients. The male and female AUD patients had similar level 
of prolactin. The female AUD patients reported more psychological 
distress (P = .002), poorer sleep condition (P = .036), and shorter 
duration of drinking (P < .001) than their male counterparts.
Table 2 presents the association of the level of prolactin of 
AUD patients with general patient characteristics, alcohol use 
trait- related factors, alcohol use state- related factors and presence 
of other substance dependence stratified on gender. Among the 
general patient characteristics, in the females, younger age was as-
sociated with higher level of prolactin (rs = −0.533, P = .002). On 
examining the influence of regular use of important dopaminergic 
drugs (all typical antipsychotics, risperidone, and amisulpride) on 
the level of prolactin, it was found that only one male AUD patient 
was on regular use of an atypical antipsychotic (levomepromazine) 
which was not associated with the level of prolactin (P = .146). We 
also examined the individual influence of regular use of other do-
paminergic drugs in the level of prolactin including atypical antipsy-
chotics (quetiapine, aripiprazole, and olanzapine), antihistamines 
(trimeprazine and promethazine), and stimulant (Methylphenidate) 
and found that the use of these drugs was not associated with the 
level of prolactin in either gender. Among the alcohol use trait- 
related factors, those females who started drinking at earlier age 
had higher level of prolactin (rs = −0.423, P = .018). In addition, the 
AUD females with the presence of other substance dependence 
measured higher on their level of prolactin (P = .018). Among the 
male AUD patients, an alcohol use trait- related factor, SRE had a 
weak positive correlation with the level of prolactin (rs = 0.302, 
P = .041).
Table 3a presents the results from the logistic regression model 
(n = 31) of level of prolactin in the female AUD patients using vari-
ables that were significantly (P < .05) or marginally (P = .075) as-
sociated with the level of prolactin for either gender in Table 2. 
Substance dependence was an exception and was not included be-
cause of fewer number in the subgroups. A younger age (OR = 0.88, 
95% CI: 0.79, 0.98) and early alcohol debut (OR = 0.59; 0.37, 0.95) in-
creased the odds of having higher prolactin levels in the female AUD 
patients. On adjusting for age, having parents with drinking problem 
(OR = 0.13; 0.02, 0.88) decreased the odds of having higher level of 
prolactin in the female AUD patients.
Table 3b presents the results from a similar logistic regression 
model (n = 81) in the male AUD patients but also including other 
substance dependence as a covariate. Presence of other substance 
dependence decreased the odds of having higher level of prolactin 
in the male AUD patients also when adjusted for age (OR = 0.29; 
0.09, 0.95).
Figure 1 presents the scatter plot between the level of prolactin 
and age at first drink in male and female AUD patients. There is a 
gender interaction in the relationship between the level of prolactin 
and age at first drink.
TA B L E  3 A   Logistic regression model of prolactin level among female AUD patients (n = 31)
n Reference Unadjusted P- values Adjusteda  P- values
Age (y) 31 Continuous OR (95% CI) 0.88 (0.79, 0.98) 0.022
Body mass index (kg/
m2)
31 Continuous OR (95% CI) 1.10 (0.97, 1.26) 0.151 1.14 (0.96, 1.35) 0.132
Parents having 
drinking problem
31 No drinking problem 
in parents
OR (95% CI) 0.22 (0.05, 1.03) 0.054 0.13 (0.02, 0.88) 0.036
Age at first drink (y) 31 Continuous OR (95% CI) 0.59 (0.37, 0.95) 0.030 0.68 (0.42, 1.12) 0.678
SRE (number of 
alcohol units to feel 
dizzy)
15 Continuous OR (95% CI) 1.34 (0.83, 2.17) 0.237 1.60 (0.84, 3.04) 0.153
Note: Values in bold indicate statistically significant results.
Abbreviations: CI, confidence interval; OR, odds ratio; SRE, self- rating of the effects of alcohol, the prolactin levels were dichotomized into high and 
low by splitting on the median value of 125 mU/L.
aAdjusted for age
358  |     PANDEY Et Al.
4  | DISCUSSION
This study of patients in remission from AUD identified similar level 
of prolactin in both genders. There were, however, gender differ-
ences in the factors associated with the level of prolactin. Among 
the general patient characteristics, a younger age predicted a higher 
level of prolactin among the female AUD patients. Among the alco-
hol use trait- related factors, an early alcohol debut and absence of 
parental drinking predicted higher level of prolactin in the female 
AUD patients. Among the male AUD patients, absence of other sub-
stance dependence predicted higher level of prolactin.
Among the general patient characteristics, in the female AUD 
patients, younger age predicted a higher level of prolactin. Estrogen 
increases prolactin secretion and its level begins to decrease before 
menopause and continues to decrease at a greater rate after meno-
pause.35 After menopause, female and male prolactin levels tends to 
be similar.37 In the present study, we observed similar level of pro-
lactin in both genders, which may reflect the age- span of the inves-
tigated patients.
Among the alcohol use trait- related factors, early alcohol debut 
predicted a higher level of prolactin only in the female AUD patients 
and a gender interaction was also observed in the relationship be-
tween the level of prolactin and age at first drink. Early alcohol use is 
found to be associated with externalizing and internalizing behaviors 
in childhood.38 In the males, early alcohol debut is mainly attributed 
to the externalizing behaviors while in the females it is mainly at-
tributed to the internalizing behaviors.39 Some studies suggest that 
an excess of dopamine makes individual more reward oriented and 
TA B L E  3 B   Logistic regression model of prolactin level among male AUD patients (n = 81)
n Reference Unadjusted P- values Adjusteda  P- values
Age (y) 81 Continuous OR (95% CI) 1.01 (0.97, 1.05) 0.688
Body mass index (kg/
m2)
81 Continuous OR (95% CI) 1.03 (0.93, 1.14) 0.569 1.03 (0.93, 1.14) 0.582
Parents having 
drinking problem
80 No drinking problem in 
parents
OR (95% CI) 1.11 (0.46, 2.66) 0.823 1.12 (0.46, 2.71) 0.800
Age at first drink (y) 80 Continuous OR (95% CI) 1.20 (0.98, 1.47) 0.085 1.20 (0.97, 1.47) 0.093
SRE (number of 
alcohol units to feel 
dizzy)
46 Continuous OR (95% CI) 1.11 (0.88, 1.39) 0.381 1.11 (0.88, 1.39) 0.380
Other substance 
dependence present
80 Absence of other 
substance dependence
OR (95% CI) 0.32 (0.12, 0.93) 0.036 0.29 (0.09, 0.95) 0.040
Note: Values in bold indicate statistically significant results.
Abbreviations: CI, confidence interval; OR, odds ratio; SRE, self- rating of the effects of alcohol, the prolactin levels were dichotomized into high and 
low by splitting on the median value of 134 mU/L.
aAdjusted for age.
F I G U R E  1   Scatter plot between the 
level of serum prolactin (milliunits per 
liter) and age at first drink (y) in male 
(n = 80) and female AUD patients (n = 31)
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thus results in externalizing behavior while others suggest that dopa-
mine deficiency in individuals drive them toward externalizing behav-
ior.40 As the direction of relationship between the level of dopamine 
and externalizing behavior is not conclusive, even in our study we 
did not find any association between age at first drink and level of 
prolactin in the male AUD patients. On the other hand, internaliz-
ing behaviors like anxiety and depression which are more related to 
early alcohol debut in the females are associated with reduced level 
of dopamine.41 Our finding of higher level of prolactin in the female 
AUD patients being associated with early alcohol debut could be ex-
plained by this linkage. On adjusting for age, the presence of parental 
drinking problem also predicted lower level of prolactin in the female 
AUD patients. Schuckit et al studied sons of AUD patients and found 
that the participants with positive family history adapt more rapidly 
to the presence of alcohol by showing a faster decrease in level of 
prolactin following a high- dose alcohol challenge.16 Possibly, for the 
same reason, we observed an association of positive family history 
of parental drinking with lower level of prolactin but only in the AUD 
daughters. Furthermore, we did not observe an association of alcohol 
use state- related factors with the level of prolactin possibly because 
the participants were abstinent for a long duration.
Among the male AUD patients, we found that the presence of 
other substance dependence predicted lower level of prolactin. 
Consistent with our findings, some literature suggests that the use 
of substances such as cannabis42 and benzodiazepines43 is associ-
ated with lower level of prolactin. In our study, the male AUD pa-
tients were more frequently dependent to cannabis (9 out of 21) but 
also to opiates (2 out of 21), cocaine/amphetamines (6 out of 21), 
and other prescription medicines (4 out of 21). However, studies in 
abstinent methamphetamine- 44 and cocaine- dependent subjects45 
demonstrated higher level of prolactin in the dependent subjects 
compared to the controls. This was also observed in the bivariate 
analysis of our female AUD patients where the presence of other 
substance dependence was associated with higher level of prolactin. 
However, caution should be held in interpreting the finding because 
there were only three patients in the group with other substance 
dependence where each of them were dependent to different sub-
stances. We suspect that rather than a gender influence, the nature 
of the substance abused might have attributed to the discrepant 
finding across genders.
The present medium- sized naturalistic study on patients in re-
mission from AUD has some limitations. General factors of impor-
tance in interpreting prolactin values such as effect of food, stress, 
exercise, and phase of menstrual cycle were not examined. However, 
literature demonstrates major role of gender, age, and BMI in prolac-
tin dynamics, all of which were examined in this study.26 The blood 
samples for prolactin estimation were collected over a wide time 
frame (8:47 AM to 4:45 PM) allowing for bias based on diurnal varia-
tion. However, there was no correlation between time of blood sam-
ple collection and the level of prolactin in our patients. On splitting 
time of blood sample collection using 12:00 mid- day as cutoff, there 
was no difference in the level of prolactin between the morning and 
afternoon samples.
In patients recovering from AUD who were abstinent for a long 
duration, we did not find an influence of alcohol use state- related 
factors in the dopamine system. Nevertheless, we still found that 
the level of prolactin (extent of dopamine dysregulation) could be 
explained by the variation in the alcohol use trait- related factors 
in one subgroup of AUD patients (females). Level of prolactin may 
reflect some of the biological drive to alcohol addiction. Having an 
idea on the different factors influencing the level of prolactin may 
help identify workable areas to minimize this drive. While it is well 
known that the very action of alcohol consumption has influence on 
the level of prolactin, our finding that in the female patients under 
remission from AUD, even the presence of alcohol use trait- related 
factors had influence on the level of prolactin, might have some 
treatment implications. Knowing about the presence of trait- related 
factors may help us understand if and why these patients are dif-
ferent in terms of outcome for a given treatment although the AUD 
symptoms they exhibit may be similar. Future research could study 
the influence of trait versus state factors in the level of prolactin 
during acute alcohol intoxication, early abstinence, and withdrawal 
to see if our findings are replicable in AUD patients with more recent 
alcohol consumption. Adding to the literature, our study also con-
veys the importance of studying different homogenous subgroup of 
AUD patients separately because we found that the variation in al-
cohol use- related trait factor was more important for the dopamine 
system in the female AUD patients. Furthermore, future research 
could include prospective studies following individuals with alcohol 
use trait- related factors from a young age so that additional traits 
influencing dopamine system other than that observed in our study 
could be identified and on doing so a more distinct gender difference 
could possibly emerge.
The sum and substance of our study is that although there is no 
gender difference in the level of prolactin among the AUD patients, 
the factors associated with the level of prolactin are gender spe-
cific. Looking at the influence of alcohol use on the level of prolactin 
among patients at the stage of remission from AUD, we conclude 
that alcohol use trait- related factors are more related to the level of 
prolactin than alcohol use state- related factors and more so in the 
females.
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